Open access

308 Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for melanoma
Jeffrey Weber, Paolo Ascierto, Mark Middleton, Delphine Hennicken, Roberto Zoffoli, Anne Pieters, Adenike Amadi, Katrin Kupas, Srividya Kotapati, Andriy Moshyk, Dirk Schadendorf

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A189-A190; DOI: 10.1136/jitc-2020-SITC2020.0308
310 The effect of pretreatment with G-CSF prior to dendritic cell collection during the phase IIb trial of an autologous DC-based vaccine for advanced, resectable melanoma
Anne O’Shea, Robert Chick, Guy Clifton, Timothy Vreeland, Lexy Adams, Patrick McCarthy, Phillip Kemp Bohan, Annelies Hickeron, John Myers, Jessica Cindass, Tommy Brown, Diane Hale, Mark Faries, John Hyngstrom, Adam Berger, James Jakub, Jeffrey Sussman, Montaser Shaheen, Thomas Wagner, George Peoples

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A191; DOI: 10.1136/jitc-2020-SITC2020.0310
312 Female sex independently predicts adjuvant immunotherapeutic benefit from CTLA4 immune checkpoint inhibition
Ahmad Tarhini, Ni Kang, Sandra Lee, F Stephen Hodi, Gary Cohen, Omid Hamid, Laura Hutchins, Jeffrey Sosman, Harriett Kluger, Zeynep Eroglu, Henry Koon, Donald Lawrence, Kari Kendra, David Minor, Carrie Lee, Mark Albertini, Lawrence Flaherty, Teresa Petrella, Howard Striecher, Vernon Sondak, John Kirkwood

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A192-A193; DOI: 10.1136/jitc-2020-SITC2020.0312
315 W0180 novel anti-VISTA antibody: Rationale for target patient population and first-in-human trial design in monotherapy and in combination with anti-PD1 antibody
Ignacio Melero, Carlos Gomez-Roca, Pierre Ferre, Pierre Ferre, Eric Chetaille, Aurelie Petain, Celine Thuilliez, Isabelle Vandenberghe, Francisco Cruzalegui, Asmaa Boudribila, Mariya Pavlyuk, Aurelien Marabelle

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A193-A194; DOI: 10.1136/jitc-2020-SITC2020.0315
317 A phase 1/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors
Leisha Emens, Muralidhar Beeram, Erika Hamilton, Sarina Piha-Paul, Valerie Odegard, Sue Hamke, Naomi Hunder, Samuel Klempner

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A195; DOI: 10.1136/jitc-2020-SITC2020.0317
319 Phase II trial of immunotherapy in primary glioblastoma: antigens from self-renewing autologous tumor cells presented by autologous dendritic cell vaccine
Daniela Bota, David Piccioni, Christopher Duma, Renato LaRocca, Santosh Kesari, Jose Carrillo, Robert O’Donnell, Robert Aiken, Frank Hsu, Xiao-Tang Kong, Thomas Taylor, Gabriel Nistor, Robert Dillman

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A196; DOI: 10.1136/jitc-2020-SITC2020.0319
320 Phase IIa study of alpha-DC1 vaccine against HER2/HER3, chemokine modulation regimen and pembrolizumab in patients with asymptomatic brain metastasis from triple negative or HER2+ breast cancer
Shipra Gandhi, Peter Forsyth, Mateusz Opyrchal, Kamran Ahmed, Hung Khong, Kristopher Attwood, Ellis Levine, Tracey O’Connor, Amy Early, Robert Fenstermaker, Dheerendra Prasad, Kazuaki Takabe, Brian Czerniecki, Pawel Kalinski

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A196-A197; DOI: 10.1136/jitc-2020-SITC2020.0320
321 Phase I clinical trial assessing the combination of systemic chemokine modulatory regimen targeting TLR3 with neoadjuvant chemotherapy in triple negative breast cancer
Shipra Gandhi, Mateusz Opyrchal, Cayla Ford, Victoria Fitzpatrick, Melissa Grimm, Per Basse, Marie Quinn, Agnieszka Witkiewicz, Kristopher Attwood, Marc Ernstoff, Tracey O’Connor, Amy Early, Ellis Levine, Pawel Kalinski

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A197; DOI: 10.1136/jitc-2020-SITC2020.0321
324 BDB001, a Toll-Like receptor 7 and 8 (TLR7/8) agonist, can be safely administered intravenously and shows clinical responses in advanced solid tumors
Manish Patel, Drew Rasco, Melissa Johnson, Anthony Tolcher, Lixin Li, Adam Zong, Alexander Chung, Robert Andtbacka

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A199; DOI: 10.1136/jitc-2020-SITC2020.0324
3 Butyrophilin-3a is expressed in multiple solid tumors: translational research supporting the EVICTION study with ICT01, an anti-BTN3A mAb activating Vg9Vd2 T-Cells
Clement Ghigo, Aude de Gassard, Patrick Brune, Caroline Imbert, Clemence Demerle, ROUVIERE Marie-Sarah, René Hoet, Daniel Olive, Emmanuel Valentin

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A2; DOI: 10.1136/jitc-2020-SITC2020.0003

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages